Tech Speeds Up Cure for Sickle Cell Disease as London Leads Global Trials

For decades, sickle cell disease has been treated largely as a lifelong condition to be managed. A donor stem-cell transplant can offer a cure, but only for a minority of patients able to find a suitable donor and undergo an intensive procedure. For many others, care has centred on pain relief, medicines, blood transfusions and […]

Sep 9, 2026 - 21:27

Tech Speeds Up Cure for Sickle Cell Disease as London Leads Global Trials

For decades, sickle cell disease has been treated largely as a lifelong condition to be managed. A donor stem-cell transplant can offer a cure, but only for a minority of patients able to find a suitable donor and undergo an intensive procedure. For many others, care has centred on pain relief, medicines, blood transfusions and the management of progressive organ damage.

That landscape is beginning to change.

For UKBlackTech, this is not a new area of interest. As we approach our tenth anniversary, UKBlackTech—and now the UKBT Institute—has spent almost a decade championing greater awareness, innovation and investment in sickle cell research, care and treatment development. We have organised hackathons that bring together academics, technologists and data scientists; engaged with NHS sickle cell groups to understand the lived experiences of patients and families; and provided a platform for health start-ups developing technologies, services and treatments that could improve the lives of people affected by the condition.

Our purpose has been to connect scientific research, technological innovation, entrepreneurship and community knowledge. That work matters because breakthroughs are most valuable when they respond to the experiences and priorities of the people they are intended to serve.

Two developments announced this week show how genomics, data science and gene editing are moving sickle cell care towards a more precise future. In England, genomic blood-group testing is now being used to select better-matched transfusions. Internationally, early clinical evidence suggests that a new form of base editing could prevent painful vaso-occlusive crises without making double-stranded cuts in DNA.

Neither development means sickle cell has been eradicated. One improves the safety of an essential treatment; the other remains an experimental therapy supported by data from a small number of patients. Together, however, they point to a significant shift: from managing the consequences of sickle cell towards intervening more precisely in its biological mechanisms.

The London blueprint: bringing genomics into routine care

NHS Blood and Transplant has announced that some of the first patients are receiving blood selected using information from England’s blood-group genotyping programme. The programme uses DNA-based testing to identify a much wider range of blood-group characteristics than conventional matching alone.

This matters because people who receive regular transfusions can develop antibodies against blood-group antigens they do not share with their donors—a process known as alloimmunisation. That can make future transfusions more difficult, increase the risk of reactions and, in some cases, leave clinicians with very few compatible units.

One of the first recipients is Tre Henry-Adegoroye, a 26-year-old entrepreneur from Lambeth who lives with severe sickle cell disease. Genotyping identified a rare variant of the RhD blood group, allowing his clinical team to select blood that is more closely matched to his profile.

The development is important not because genomics has suddenly replaced transfusion medicine, but because it is becoming part of frontline healthcare logistics. NHS Blood and Transplant says around 17,000 people with sickle cell disease and 800 people with thalassaemia are being offered the test. The programme is being delivered with NHS England, with University College London Hospitals helping to develop the testing proposal and support from the NIHR Biomedical Research Centre at UCLH.

London is particularly important to this work. It has one of Europe’s largest concentrations of people living with sickle cell disease, with South London alone accounting for more than 3,800 people living with or receiving care for the condition. That concentration of patients, specialist NHS services, universities and research expertise makes the capital an important centre for developing and evaluating better care.

Beyond molecular scissors: the promise of base editing

A second breakthrough has come from an international research team working with CorrectSequence Therapeutics. A study published online in Cell Stem Cell reports early clinical results for therapies based on the company’s transformer Base Editor platform.

The distinction from first-generation CRISPR editing is important. Treatments such as Casgevy use CRISPR-Cas9 to create a targeted double-stranded break in DNA. Base editing can change selected DNA letters without cutting both strands of the DNA molecule—more like altering characters in a line of code than cutting the line apart.

The CorrectSequence therapy does not simply replace the sickle cell mutation with a “healthy letter”. It edits regulatory regions associated with the production of foetal haemoglobin. By reactivating this form of haemoglobin, the treatment aims to compensate for the defective adult haemoglobin that causes red blood cells to sickle.

The newly published study involved four patients from Nigeria, Laos, Malaysia and Pakistan: one with sickle cell disease and three with transfusion-dependent beta-thalassaemia. The 21-year-old Nigerian woman with sickle cell disease had experienced more than four vaso-occlusive crises in the year before treatment. At 15.5 months of follow-up, researchers reported that she had experienced none. The three patients with beta-thalassaemia achieved sustained transfusion independence.

Researchers reported no detectable off-target edits or treatment-product-related adverse events in this small cohort. That is encouraging, but it should not be translated into a claim of zero risk. Larger studies, longer follow-up and independent regulatory scrutiny will be essential before the treatment’s safety, durability and applicability can be understood fully.

Innovation must include the people most affected

Scientific progress alone will not correct the historic inequalities surrounding sickle cell care. The condition disproportionately affects people of African and Caribbean heritage, yet patients have repeatedly reported underinvestment, unequal treatment and poor experiences within healthcare. The NHS Race and Health Observatory has found significant disparities in research funding, specialist staffing and access to treatment when sickle cell is compared with conditions such as cystic fibrosis.

This is where community-led organisations have a vital role to play. The UKBT Institute does not claim ownership of the science; our role is to build the connective tissue around it and help ensure that lived experience informs research, investment and implementation. If new treatments are designed without the communities most affected by the condition, innovation risks reproducing the inequalities it is supposed to solve.

The Commercial Bottleneck

The central question is no longer whether gene editing can alter the course of sickle cell disease. Casgevy is already available to eligible NHS patients in England, and base-editing platforms are producing promising early clinical evidence. The harder questions concern eligibility, treatment capacity, long-term safety, manufacturing and cost.

Casgevy has a UK list price of £1.65 million per patient, although the NHS has negotiated a confidential discount. Treatment also requires patients’ stem cells to be collected and edited outside the body, followed by intensive conditioning before the modified cells are returned. This demands specialist facilities, trained clinical teams and extended follow-up; it is not a therapy that can be scaled like a conventional tablet.

Those constraints are particularly serious in lower-income countries, including many in sub-Saharan Africa, where the burden of sickle cell disease is greatest and advanced transplant infrastructure is limited. A treatment can be scientifically transformative while remaining socially inaccessible.

The next phase of sickle cell innovation must therefore combine discovery with delivery. It will require better genomic data, safer and more efficient editing platforms, more representative clinical trials, stronger treatment infrastructure and pricing models that do not reserve curative medicine for wealthy health systems.

The science is moving quickly. The measure of progress, however, will not be whether a cure can be demonstrated in a laboratory or a small clinical study. It will be whether the people who have waited longest for investment can benefit from it safely, affordably and at scale.